MarketCap
Facebook
X
TelegramQuartalsbericht 2025-Q3
hinzugefügt 06.11.2025
Sangamo Therapeutics Operativer Cashflow 2011-2026 | SGMO
Operativer Cashflow Jährlich Sangamo Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -225 M | -224 M | -233 M | 170 M | -144 M | 36.6 M | 11.2 M | -65.9 M | - | - | -19.5 M | -8.08 M | -25.9 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 170 M | -233 M | -66.2 M |
Operativer Cashflow Vierteljährlich Sangamo Therapeutics
| 2025-Q3 | 2025-Q2 | 2024-Q3 | 2024-Q2 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | -66.3 M | - | -167 M | - | -59 M | - | -181 M | - | -68.6 M | - | 174 M | 141 M | -18.9 M | - | -124 M | -84.7 M | -45.1 M | - | 76.7 M | 104 M | -18.1 M | - | 28 M | 43.7 M | - | - | - | - | - | - | - | - | - | - | - | - | 11.4 M | - | - | - | -8.02 M | - | -8.3 M | -3.15 M | 2.87 M | - | -25.9 M | -19.4 M | -12 M |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 174 M | -181 M | -13.6 M |
Operativer Cashflow anderer Aktien in der Pharmaeinzelhändler
| Name | Operativer Cashflow | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
-57.8 M | - | 1052.0 % | $ 415 M |  USA |
 |
Acasti Pharma
ACST
|
-14.9 M | - | 4.01 % | $ 150 M |  Canada |
 |
AC Immune SA
ACIU
|
-65.7 M | $ 2.72 | 7.51 % | $ 229 M |  Schweiz |
 |
Adverum Biotechnologies
ADVM
|
-92.5 M | - | - | $ 86.2 M | USA |
 |
AgeX Therapeutics
AGE
|
-7.8 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
-15.1 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aptorum Group Limited
APM
|
-1.19 M | $ 0.81 | 1.28 % | $ 4.42 M |  China |
 |
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M | China |
 |
argenx SE
ARGX
|
-607 M | $ 840.28 | 1.7 % | $ 25 B |  Niderland |
 |
Ascendis Pharma A/S
ASND
|
-418 M | $ 234.99 | 0.02 % | $ 5 B |  Danmark |
 |
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | USA |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M |  France |
 |
Albireo Pharma
ALBO
|
-108 M | - | -0.23 % | $ 916 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-12.3 M | $ 3.33 | 0.79 % | $ 8.01 B |  Australia |
 |
Atea Pharmaceuticals
AVIR
|
-135 M | $ 4.65 | 1.31 % | $ 392 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-45.7 M | - | 3.16 % | $ 1.9 M | USA |
 |
AlloVir
ALVR
|
-67.7 M | - | 4.14 % | $ 49.1 M | USA |
 |
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Akouos
AKUS
|
-63.7 M | - | 0.23 % | $ 488 M | USA |
 |
BioVie
BIVI
|
-19 M | $ 1.25 | - | $ 1.85 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-8.56 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
-93.9 M | - | - | $ 10.1 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
573 M | $ 62.62 | -0.48 % | $ 11.9 B | USA |
 |
Acorda Therapeutics
ACOR
|
-14 M | - | -24.86 % | $ 820 K | USA |
 |
Acer Therapeutics
ACER
|
-30.3 M | - | 2.71 % | $ 14 M | USA |
 |
Aravive
ARAV
|
-65.1 M | - | -13.39 % | $ 1.45 M | USA |
 |
Capricor Therapeutics
CAPR
|
-25.6 M | $ 27.91 | 0.14 % | $ 747 M | USA |
 |
CASI Pharmaceuticals
CASI
|
-26.8 M | $ 0.8 | 5.68 % | $ 109 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-65.7 M | - | - | $ 26.5 M | USA |
 |
Avenue Therapeutics
ATXI
|
-9.03 M | - | -52.27 % | $ 4.45 M | USA |
 |
Catalyst Biosciences
CBIO
|
25.9 M | $ 12.65 | 10.29 % | $ 833 M | USA |
 |
Axsome Therapeutics
AXSM
|
-93.4 M | $ 169.95 | -2.75 % | $ 8.45 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-34.5 M | - | - | $ 7.46 M |  Israel |
 |
Atreca
BCEL
|
-80.7 M | - | -11.76 % | $ 5.79 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-43.8 M | - | - | $ 2.17 B | USA |
 |
BioDelivery Sciences International
BDSI
|
41 M | - | -4.8 % | $ 255 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.58 M | - | 5.93 % | $ 314 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
-141 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Biogen
BIIB
|
2.2 B | $ 195.13 | -0.62 % | $ 28.6 B | USA |
 |
Cellectis S.A.
CLLS
|
-105 M | $ 3.98 | 0.51 % | $ 116 M | France |
 |
Bellicum Pharmaceuticals
BLCM
|
-25.8 M | - | -9.72 % | $ 5.89 M | USA |
 |
Baudax Bio
BXRX
|
-27.8 M | - | 0.59 % | $ 63 K | USA |
 |
Aptose Biosciences
APTO
|
-36 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-59.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
Cellectar Biosciences
CLRB
|
-32.4 M | $ 3.36 | 3.07 % | $ 41.1 M | USA |